Day: May 12, 2023

Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2023 and provided an update on recent corporate developments. “We continue to make important progress advancing our clinical programs as we await topline results from several key cohorts in our Phase 1/1b study of BP1001-A in solid tumors, Phase 1/1b study of BP1002 in relapsed/refractory AML, and Phase 2 study of prexigebersen in AML,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. “Despite advances in the field, cancer deaths...

–Registration Trial for uUTI Ongoing and On Track– –Cash Runway until Mid-2024– DUBLIN, Ireland and CHICAGO, May 12, 2023 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March 31, 2023. “We remain on track to complete enrollment in our REASSURE trial in the first half of next year with over 100 sites currently open to enrollment and a plan to add another 40-70 clinical trial sites,” said Corey Fishman, Iterum’s Chief Executive Officer. “Top-line data is expected soon after enrollment is completed, with a potential resubmission...

ORLANDO, Fla., May 12, 2023 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American LLC: GENC) announced today net revenues of $30,501,000 for the quarter ended March 31, 2023 compared to $30,654,000 for the quarter ended March 31, 2022. Gross profit margins for the quarter ended March 31, 2023 were 29.8% compared with 20.2% for the quarter ended March 31, 2022 on increased efficiency, absorption and favorable price realization. Product engineering and development expenses decreased $46,000 to $874,000 for the quarter ended March 31, 2023, as compared to $920,000 for the quarter ended March 31, 2022, primarily related to reduced headcount. Selling, general and administrative (“SG&A”) expenses decreased by $302,000 to $3,062,000 for the quarter ended March 31, 2023, compared to $3,364,000 for the...

Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023Phase 1 trial for SGT-210 (erlotinib) demonstrated no systemic absorption-related adverse events; Sol-Gel intends to advance this drug candidateSol-Gel has cash runway into the second half of 2025NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products, EPSOLAY and TWYNEO, that were launched in the U.S., SGT-610, which is Phase 3-ready, and an earlier-stage SGT-210, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate...

All amounts in U.S. dollars unless otherwise stated TORONTO, May 12, 2023 (GLOBE NEWSWIRE) — Onex Corporation (TSX: ONEX) today announced its financial results for the first quarter ended March 31, 2023. On May 11, 2023, Bobby Le Blanc was appointed Chief Executive Officer of Onex following shareholder approval of the MVS amendment proposal at the company’s annual meeting. “We are moving forward with targeted initiatives to reinvigorate growth, drive positive outcomes for our partners and accelerate the value creation process,” said Bobby Le Blanc, Chief Executive Officer. “With nearly $8 billion of invested capital, a debt-free balance sheet and our entrepreneurial culture, we are well positioned to grow Onex’ intrinsic value.” Financial Results(unaudited)($ millions except per share amounts) Three Months Ended March 31, 2023 Three...

– Updates 2023 Revenue Guidance to $25-$30 Million– HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) — Freight Technologies, Inc. (Nasdaq: FRGT) (“Fr8Tech”), a technology company offering its custom-developed Fr8App, an industry-leading freight-matching platform powered by AI and machine-learning that offers a real-time portal for B2B cross-border and domestic shipping within the USMCA region, today reports first quarter 2023 revenue for the quarter ended March 31, 2023. Fr8Tech reported preliminary revenue of $3.3 million for Q1 2023, down from a strong $5.3 million for Q1 prior year 2022. The Q1 year-over-year revenue decline was caused by a temporal decline in capacity available to the Fr8fleet during the first quarter in Mexico versus the prior year, the loss of a key cross-border account during the latter part of 2022 and the...

Total Revenue of $69.9 Million, an increase of 12.9% YoY Net Loss of $12.4 Million, an improvement of 37.0% YoY Adjusted EBITDA of $7.6 Million, an improvement of $8.5 Million YoY Continued Financial and Operational Improvements at our Grower-Processor Operations Added Ohio as Fifth Vertically Integrated Market BOCA RATON, Fla., May 12, 2023 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, is pleased to announce its financial results for the first quarter ended March 31, 2023 (“Q1 2023”). All financial information is unaudited and provided in U.S. dollars unless otherwise indicated and is prepared under U.S. Generally Accepted Accounting Principles (“GAAP”). First Quarter 2023 Financial Highlights1Total revenue of $69.9 million,...

SAN FRANCISCO, May 12, 2023 (GLOBE NEWSWIRE) — Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions to healthcare systems, physician practices, hospitals, and telemedicine practitioners, today reported financial results for the three months ended March 31, 2023. “Augmedix begins 2023 with continued commercial momentum, increasing operating leverage, and a landmark strategic partnership and financing with HCA Healthcare, Inc., one of the nation’s leading healthcare providers,” commented Manny Krakaris, Chief Executive Officer at Augmedix. “Together with HCA Healthcare, we are accelerating the development of technology such as Augmedix Go that aims to transform the way patient care is documented in the acute care setting. This collaboration...

— ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment, with Data Expected in 1H 2024 — — Data from BEACON Phase 2 Trial of LYR-220 in Post-Surgical CRS Anticipated Q4 2023 — WATERTOWN, Mass., May 12, 2023 (GLOBE NEWSWIRE) — Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today reported its financial results for the first quarter ended March 31, 2023 and provided a corporate update. “We’ve had a highly productive start to 2023, positioning us for anticipated key data readouts over the next 12 months,” said Maria Palasis, Ph.D., President and CEO of Lyra. “Enrollment is progressing well in...